Table of Contents
What This AI Powered Haemodialysis Machines Approval Means
New Delhi, India’s Lords Mark Industries Ltd., in partnership with Renalyx, has won approval to manufacture AI powered haemodialysis machines under Class C medical device rules. The approval also comes with a global CE mark. This step strengthens India’s role in medical device innovation and high risk healthcare technology.
Lords Mark Industries now holds a licence from the Central Drugs Standard Control Organisation (CDSCO) to produce Class C smart haemodialysis machines. Class C devices are life-sustaining and carry high risk if not safe. With CE certification, these machines meet strict European safety and quality standards.
This dual approval makes Lords Mark one of the few global firms able to manufacture this class of advanced devices. It also supports India’s push to rely less on imports for critical healthcare tools.
Why AI Powered Haemodialysis Machines Matter
Modern dialysis machines use data and automated controls to guide treatment. Those labelled AI powered haemodialysis machines can adjust fluid removal, monitor vital markers, and alert clinicians to possible issues. These features help make care more precise and safer for patients with chronic kidney disease.
Hospitals can use machine data to tune treatments, reduce human errors, and help nephrologists make fast decisions. In countries with rising renal disease rates, such tools can improve outcomes and reduce costs.
AI and Machine Learning Devices Sit in a Partial Regulatory Grey Zone
The EU’s AI Act and the EU MDR were developed on separate tracks and are not yet fully harmonised for adaptive AI medical devices. A CE marked AI haemodialysis machine today meets the standards that existed at the time of its approval, but the regulatory framework itself is still being refined.
This is not a reason to avoid the technology it is a reason to build contract terms and procurement agreements that include post market surveillance obligations and software update governance clauses.
Cybersecurity Is a Patient Safety Issue, Not a Peripheral IT Concern
Connected AI haemodialysis machines transmit patient physiological data, receive software updates, and in some configurations interface with hospital network infrastructure. Each of those functions is a potential attack surface. The 2024 cyberattacks on hospital IoT infrastructure across European health systems demonstrated that connected medical devices are active targets.
A haemodialysis machine that loses connectivity during a session due to a network level attack, or that receives a malicious firmware update through a compromised update channel, poses direct patient harm risk. Device procurement should include a cybersecurity assessment as standard, not optional.
Industry Perspective
Sachidanand Upadhyay, Managing Director of Lords Mark Industries Ltd., said this approval is more than a licence. He noted it shows India’s ability to compete with global med tech leaders and deliver high quality, safe devices. Such devices can help hospitals reduce dependency on foreign equipment while boosting local research and manufacturing.
Real World Patient Benefit
For people needing long-term dialysis, machine performance can directly affect health. Faster alarms and adaptive treatment settings mean fewer complications during sessions. The rise of AI enabled monitoring in these systems marks a clear step toward quality care improvements.
Broader Healthcare Context
India faces a growing burden of chronic kidney disease. Dialysis centres are limited, and many regions rely on imported machines. With AI based haemodialysis machines now approved for local production, supply resilience and technology access can improve significantly.
Local production aligned with international standards can also help exports and increase global competitiveness in the med-tech sector.
“Securing both the licence and CE mark not only supports India’s healthcare self reliance, but also signals trust in advanced AI based haemodialysis machines to improve patient outcomes.” Sachidanand Upadhyay, Managing Director, Lords Mark Industries Ltd.
What to Watch Next
Healthcare groups and hospitals will soon assess how these machines perform in real settings. Watch for announcements about rollout plans, hospital pilot programs, and clinical safety data. These steps will shape adoption pace and patient access.
Disclaimer
This article reflects analysis based on publicly available regulatory filings, medical device governance frameworks, and clinical literature current as of May 2026. It does not constitute medical or legal advice. Clinical deployment decisions should involve qualified regulatory affairs, biomedical engineering, and legal professionals.
Noman Akram is the Founder and Editor-in-Chief of TWT News. He is a technology journalist with 5+ years of experience covering artificial intelligence, AI in healthcare, blockchain, cloud computing, and cybersecurity. He built TWT News to make complex emerging technologies understandable for professionals, students, and business leaders. Based in UK (United Kingdom), his reporting covers global tech developments with a focus on real world impact.